A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb

被引：0
|
作者：
Joy, Stephen T. [1 ]
Henley, Matthew J. [1 ,2 ]
De Salle, Samantha N. [1 ,2 ]
Beyersdorf, Matthew S. [1 ,2 ]
Vock, Isaac W. [1 ,3 ]
Huldin, Allison J. L. [1 ,4 ]
Mapp, Anna K. [1 ,2 ,4 ]
机构：
[1] Joy, Stephen T.
[2] 1,Henley, Matthew J.
[3] 1,De Salle, Samantha N.
[4] 1,Beyersdorf, Matthew S.
[5] 1,Vock, Isaac W.
[6] 1,Huldin, Allison J. L.
[7] 1,2,Mapp, Anna K.
来源：
Mapp, Anna K. (amapp@umich.edu) | 1600年 / American Chemical Society卷 / 143期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Journal article (JA)
引用
收藏
页码：15056 / 15062
相关论文
共 50 条
  • [31] Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300
    Uttarkar, Sagar
    Dukare, Sandeep
    Bopp, Bertan
    Goblirsch, Michael
    Jose, Joachim
    Klempnauer, Karl-Heinz
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (06) : 1276 - 1285
  • [32] Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
    Thomas, Junius Eugene
    Wang, Mi
    Jiang, Wei
    Wang, Meilin
    Wang, Lu
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (12) : 8178 - 8199
  • [33] Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction
    Uttarkar, Sagar
    Dasse, Emilie
    Coulibaly, Anna
    Steinmann, Simone
    Jakobs, Anke
    Schomburg, Caroline
    Trentmann, Amke
    Jose, Joachim
    Schlenke, Peter
    Berdel, Wolfgang E.
    Schmidt, Thomas J.
    Mueller-Tidow, Carsten
    Frampton, Jon
    Klempnauer, Karl-Heinz
    BLOOD, 2016, 127 (09) : 1173 - 1182
  • [34] FT-6876, a potent and selective inhibitor of CBP/p300 with antitumor activity in AR-positive breast cancer
    Caligiuri, Maureen
    Williams, Grace L.
    Castro, Jennifer
    Battalagine, Linda
    Muskiewicz, Kristina
    Wilker, Erik
    Yao, Lili
    Schiller, Shawn
    Toms, Angela
    Li, Ping
    Pardo, Eneida
    Graves, Bradford
    Wood, Kenneth W.
    Guichard, Sylvie M.
    CANCER RESEARCH, 2020, 80 (16)
  • [35] Discovery of a selective catalytic p300/CBP inhibitor that targets lineage specific tumours (vol 550, pg 128, 2017)
    Lasko, Loren M.
    Jakob, Clarissa G.
    Edalji, Rohinton P.
    Qiu, Wei
    Montgomery, Debra
    Digiammarino, Enrico L.
    Hansen, T. Matt
    Risi, Roberto M.
    Frey, Robin
    Manaves, Vlasios
    Shaw, Bailin
    Algire, Mikkel
    Hessler, Paul
    Lam, Lloyd T.
    Uziel, Tamar
    Faivre, Emily
    Ferguson, Debra
    Buchanan, Fritz G.
    Martin, Ruth L.
    Torrent, Maricel
    Chiang, Gary G.
    Karukurichi, Kannan
    Langston, J. William
    Weinert, Brian T.
    Choudhary, Chunaram
    de Vries, Peter
    Kluge, Arthur F.
    Patane, Michael A.
    Van Drie, John H.
    Wang, Ce
    McElligott, David
    Kesicki, Edward A.
    Marmorstein, Ronen
    Sun, Chaohong
    Cole, Philip A.
    Rosenberg, Saul H.
    Michaelides, Michael R.
    Lai, Albert
    Bromberg, Kenneth D.
    NATURE, 2018, 558 (7710) : E1 - E1
  • [36] Another One (of the "Undruggable" Targets) Bites the Dust: Discovery of a Potent and Selective Inhibitor of the Histone Acetyl Transferase p300/CBP
    Kodadek, Thomas
    BIOCHEMISTRY, 2018, 57 (06) : 899 - 900
  • [37] E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells
    Bayly, R
    Chuen, L
    Currie, RA
    Hyndman, BD
    Casselman, R
    Blobel, GA
    LeBrun, DP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (53) : 55362 - 55371
  • [38] An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells
    Gu, Meng-Li
    Wang, Ya-Mei
    Zhou, Xin-Xin
    Yao, Hang-Ping
    Zheng, Song
    Xiang, Zun
    Ji, Feng
    ONCOLOGY REPORTS, 2016, 36 (05) : 2763 - 2770
  • [39] IACS-16559, a CBP/P300 bromodomain inhibitor for the treatment of specific AML subsets
    Zanca, Ciro
    Soth, Michael
    Gao, Guang
    Gay, Jason
    Feng, Ningping
    Bristow, Christopher
    Le, Kang
    Xu, Quanyun
    Phuong Nguyen
    Jiang, Yongying
    Perry, Teresa
    Mseeh, Faika
    Leonard, Paul
    Cross, Jason
    Giuliani, Virginia
    Marszalek, Joe
    Jones, Philip
    Heffernan, Tim
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Discovery of a potent catalytic p300/CBP inhibitor that targets lineage-specific tumors
    Bromberg, Kenneth D.
    Lasko, Loren M.
    Jakob, Clarissa G.
    Qiu, Wei
    Montgomery, Debra
    Digiammarino, Enrico L.
    Hansen, Todd M.
    Risi, Roberto M.
    Frey, Robin R.
    Manaves, Vlasios
    Shaw, Bailin
    Algire, Mikkel
    Hessler, Paul
    Lam, Lloyd T.
    Uziel, Tamar
    Favire, Emily
    Ferguson, Debra
    Buchanan, Fritz G.
    Martin, Ruth L.
    Torrent, Maricel
    Rosenberg, Saul H.
    Michaelides, Michael R.
    Lai, Albert
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345